Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-10Clinical Trial Update: A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma [Phase 3]
Phase III trial evaluating elotuzumab in VRD induction/consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma has c…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) [Phase 2]
A Phase 2 trial evaluating a dendritic cell/myeloma fusion vaccine for multiple myeloma has completed enrollment, with results posted in 202…
-
CLINICAL_TRIALS trial_result · 2021-09-09Clinical Trial Update: T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma [Phase 1]
Phase 1 trial evaluating T-cells expressing an anti-SLAMF7 CAR for treating multiple myeloma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-09-02Clinical Trial Update: Nonmyeloablative Haploidentical Transplant Followed by MLN9708 [Phase 2]
Phase 2 trial evaluating nonmyeloablative haploidentical transplant followed by MLN9708 (ixazomib) in various hematologic malignancies compl…
-
FDA approval · 2021-08-31FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation. The action expands or updates the …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-08-27Clinical Trial Update: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency [Phase 2]
Phase 2 trial updating efficacy and safety of pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma with renal insufficien…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating MP0250 in combination with bortezomib and dexamethasone for relapsed multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-23Clinical Trial Update: A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma [Phase 2]
Phase 2 pilot trial investigating the interaction between apixaban and dexamethasone in multiple myeloma was terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide [Phase 4]
Phase 4 clinical trial update evaluating pomalidomide combined with dexamethasone and ixazomib in relapsed multiple myeloma patients previou…
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) [Phase 2]
Phase 2 MATCH subprotocol evaluates binimetinib as a targeted treatment for cancers with NRAS alterations; results were posted in 2021 and t…
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 trial update on the efficacy of the BAd regimen in relapsed and refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) [Phase 2]
Phase 2 trial of vorinostat, bortezomib, and dexamethasone in multiple myeloma completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Phase I/II Study of hLL1 in Multiple Myeloma [Phase 1, Phase 2]
Phase I/II study of hLL1 in multiple myeloma has completed its phases.
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) [Phase 2]
A Phase 2 MATCH subprotocol evaluating AZD5363 (capivasertib) for cancers with AKT genetic alterations; the study is marked as active but no…
-
FDA approval · 2021-08-09FDA Approved: EVOMELA — Supplemental Application (Acrotech Biopharma Inc)
FDA approves a supplemental application for EVOMELA (melphalan) from Acrotech Biopharma Inc.
-
CLINICAL_TRIALS trial_result · 2021-08-09Clinical Trial Update: Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) [Phase 2]
A Phase 2 trial evaluating panobinostat (LBH589) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation …
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.
-
FDA approval · 2021-08-05FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2021-08-05Clinical Trial Update: Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M) [Phase 2]
Phase 2 trial investigating radiotherapy with immunotherapy for systemic effects in multiple myeloma; the study was terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating Venetoclax in Subjects With Hematological Malignancies [Phase 1, Phase 2]
Clinical trial update for venetoclax in hematological malignancies at phases 1 and 2; study status completed.
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody [Phase 1, Phase 2]
First-in-human imaging study of 89Zr-DFO-daratumumab targeting CD38 in multiple myeloma; study completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-30Clinical Trial Update: Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A combined phase 1/2 trial of pomalidomide, dexamethasone, and filgrastim-sndz in relapsed or refractory multiple myeloma has been terminate…
-
CLINICAL_TRIALS trial_result · 2021-07-22Clinical Trial Update: Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients [Phase 1]
Phase I dose-escalation study of BI 836909 monotherapy in last-line multiple myeloma completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-14Clinical Trial Update: Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma [Phase 2]
Phase 2 trial update on LBH589B for adult multiple myeloma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.